Navigation Links
Entremed Presents Results of ENMD-2076 Phase 1 Study in Advanced Cancer Patients
Date:6/1/2009

nic kinase inhibitor, for the treatment of cancer. ENMD-2076 is currently in Phase 1 studies in advanced cancers and multiple myeloma. The Company's other therapeutic candidates include MKC-1, an oral cell-cycle regulator with activity against the mTOR pathway currently in multiple Phase 2 clinical trials for cancer, and ENMD-1198, a novel antimitotic agent currently in Phase 1 studies in advanced cancers. The Company also has an approved IND application for Panzem(R) in rheumatoid arthritis. Additional information about EntreMed is available on the Company's web site at www.entremed.com and in various filings with the Securities and Exchange Commission.

Forward Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance (including the timing of royalty revenues and future R&D expenditures), strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in Securities and Exchange Commission filings under "Risk Factors," including risks relating to the need for additional capital and the uncertainty of additional funding; variations in actual sales of Thalomid(R), risks associated with the Company's product candidates; the early-stage products under development; results in preclinical models are not necessarily indicative of clinical results, uncertainties relating to preclinical and clinical trials; success in the clinical development of any products; dependence on third
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. EntreMed Presents Initial Clinical Results for ENMD-2076
2. EntreMed Receives New Patent for 2-Methoxyestradiol Analogs
3. EntreMed Presents MKC-1 Phase 2 Data at American Society of Clinical Oncology Annual Meeting
4. EntreMed Presents MKC-1 and ENMD-1198 Preclinical Data at AACR Annual Meeting
5. EntreMed to Highlight ENMD-2076 Kinase Inhibitor at 2008 AACR Annual Meeting
6. EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical Program
7. EntreMed Commences Continuous Dosing Clinical Trial For MKC-1
8. EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers
9. EntreMed to Present at The New York Society of Security Analysts Industry Conference
10. EntreMed Commences Phase 2 Study with MKC-1 in Pancreatic Cancer
11. EntreMed Shows Increased Survival With MKC-1 in Preclinical Renal Cell Cancer Model
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... -- Biosimilars are not generics and the Biologics ... Drug Administration (FDA) for recognizing that each biosimilar ... issued today. The FDA,s draft guidance on nonproprietary ... for biological products to bear a nonproprietary name ... the agency,s thinking that "there is a need ...
(Date:8/27/2015)... 2015  Now that Intuitive Surgical, Inc.® has announced ... robot, hospitals with robotic surgery programs need to think ... see where they stand with robotic surgery. Are they ... they adopted best practices for safety? Should they plan ... ECRI Institute, which has nearly 50 years, ...
(Date:8/27/2015)... , Aug. 27, 2015  A mere one ... Booz Allen Hamilton . A new white ... development inefficiencies are impeding and disrupting manufacturers, success. ... Waste and Improve Value In Product Development Processes ... inaccessible data and how it affects the product development ...
Breaking Medicine Technology:Biologics Prescribers Collaborative (BPC) Statement on FDA Draft Guidance entitled "Nonproprietary Naming of Biological Products" 2ECRI Institute's New Robotic Surgery Service Helps Hospitals Brace for Change 2ECRI Institute's New Robotic Surgery Service Helps Hospitals Brace for Change 3New White Paper Reveals How Manufacturers Can Improve Product Development Processes 2
... Incorporated (NASDAQ: GPRO ) announced today that the Company ... 28, 2011 at approximately 4:00 pm Eastern Time (ET). The announcement ... pm ET.   The conference call will be webcast ... Company,s web site at www.gen-probe.com . An archived version of ...
... July 14, 2011 Span-America Medical Systems, Inc. (NASDAQ: ... rebroadcast of its conference call on Friday, July 29, 2011, ... be released after the regular close of trading the preceding ... will be available online at www.spanamerica.com under investor ...
Cached Medicine Technology:Gen-Probe Announces Webcast of Second Quarter 2011 Earnings Conference Call 2
(Date:8/27/2015)... ... , ... Mesa Community College graduate, Andrew Sypher (Mesa), is one ... rigor, leadership and engagement, to receive a Phi Theta Kappa 2015 Hites Transfer Scholarship, ... medallion and a $7,500 scholarship to assist in his goal of becoming a foreign ...
(Date:8/27/2015)... ... August 27, 2015 , ... ... cost to treat a patient with hemophilia is $175,000. Hemophilia is an inherited, ... and improving treatment. The RMHBDA exists to help raise funds for patients suffering ...
(Date:8/27/2015)... ... 2015 , ... According to an article published August 13 by ... many conversations between hernia experts surrounding the search for the ideal hernia mesh. With ... experts have different ideas about which is the best mesh for their patients. What ...
(Date:8/27/2015)... Denver, CO (PRWEB) , ... August 27, 2015 , ... ... author examined the current policing situation in the city of New Orleans, highlighting a ... Force, the firm is run by a tech oriented entrepreneur who worked with the ...
(Date:8/27/2015)... , ... August 27, 2015 , ... ... , is one of just 20 adult-only medical centers in the United States ... with failing hearts and lungs. The Extracorporeal Life Support Organization (ELSO) , ...
Breaking Medicine News(10 mins):Health News:Mesa Community College Graduate Andrew Sypher Receives Hites Transfer Scholarship 2Health News:Mesa Community College Graduate Andrew Sypher Receives Hites Transfer Scholarship 3Health News:Avitus Group Encourages Business & Employee Community Involvement; Senior Level Staff Leads Way With Support of Rocky Mountain Hemophilia & Bleeding Disorders Association 2Health News:Avitus Group Encourages Business & Employee Community Involvement; Senior Level Staff Leads Way With Support of Rocky Mountain Hemophilia & Bleeding Disorders Association 3Health News:Avitus Group Encourages Business & Employee Community Involvement; Senior Level Staff Leads Way With Support of Rocky Mountain Hemophilia & Bleeding Disorders Association 4Health News:Recent Article on Hernia Mesh Developments Highlights Viable Options, But Shows a Need for Further Research, notes Dr. Shirin Towfigh 2Health News:Article on New Orleans Security Force Highlights the Abilities and Flexibility of Private Security, says Spear Security Inc. 2Health News:International Organization Honors Allegheny General Hospital's Advanced Lifesaving Program for Cardiac and Respiratory Failure 2Health News:International Organization Honors Allegheny General Hospital's Advanced Lifesaving Program for Cardiac and Respiratory Failure 3Health News:International Organization Honors Allegheny General Hospital's Advanced Lifesaving Program for Cardiac and Respiratory Failure 4
... family history data supports heredity,s role in shoulder tendon tearsROSEMONT, ... rotator cuff tears are at increased ... published in the May 2009 issue of The ... (JBJS). "This strongly suggests genetic predisposition as a possible cause ...
... crisis improved long-term outcomes, study found , , FRIDAY, May ... drug during a coronary emergency can save lives and ... , The one-year risk of death or major heart ... episodes of acute coronary syndrome who received the drugs, ...
... Mexico -- thought to be source of outbreak -- reports ... -- The number of confirmed swine flu cases in the ... but the infections continue to be mild. , In response ... for all Americans against the never-before-seen flu strain, but the ...
... Presented at American Heart Association ATVB Conference Shows Reduction ... in Treated PatientsWASHINGTON and SAN FRANCISCO, May 1 ... announced the results of a sub-study of patients in ... received serial 64 slice multidetector computed tomography (MDCT) scans ...
... a leading online consumer advocacy group, has announced the ... skin care and anti-aging websites, http://www.NewImageSpecialists.com ... cosmetic market, New Image Specialists, growing popularity has led ... network of more than 300 medical spas and laser ...
... 1 SCOLR Pharma, Inc. (NYSE Amex: DDD ... 31, 2009. The Company will host a live conference ... Time).Bruce S. Morra, SCOLR Pharma,s President and CEO, stated, "Our ... lead product candidates, ibuprofen and pseudoephedrine, and the support of ...
Cached Medicine News:Health News:Rotator Cuff Tears: Are They All in the Family? 2Health News:Rotator Cuff Tears: Are They All in the Family? 3Health News:Cholesterol Drugs May Help in Cardiac Emergency 2Health News:Swine Flu Infections Near 110 in U.S. 2Health News:Swine Flu Infections Near 110 in U.S. 3Health News:Swine Flu Infections Near 110 in U.S. 4Health News:Swine Flu Infections Near 110 in U.S. 5Health News:Swine Flu Infections Near 110 in U.S. 6Health News:Swine Flu Infections Near 110 in U.S. 7Health News:VIA Pharmaceuticals Announces Positive Phase 2 Results of VIA-2291 in Cardiovascular Patients Using Serial MDCT Imaging of Coronary Plaque 2Health News:VIA Pharmaceuticals Announces Positive Phase 2 Results of VIA-2291 in Cardiovascular Patients Using Serial MDCT Imaging of Coronary Plaque 3Health News:VIA Pharmaceuticals Announces Positive Phase 2 Results of VIA-2291 in Cardiovascular Patients Using Serial MDCT Imaging of Coronary Plaque 4Health News:VIA Pharmaceuticals Announces Positive Phase 2 Results of VIA-2291 in Cardiovascular Patients Using Serial MDCT Imaging of Coronary Plaque 5Health News:SignatureForum Introduces NewImageSpecialists.com 2Health News:SCOLR Pharma, Inc. Reports First Quarter 2009 Financial Results 2Health News:SCOLR Pharma, Inc. Reports First Quarter 2009 Financial Results 3Health News:SCOLR Pharma, Inc. Reports First Quarter 2009 Financial Results 4Health News:SCOLR Pharma, Inc. Reports First Quarter 2009 Financial Results 5Health News:SCOLR Pharma, Inc. Reports First Quarter 2009 Financial Results 6Health News:SCOLR Pharma, Inc. Reports First Quarter 2009 Financial Results 7
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: